Catalog No.S1070

PHA-665752 Chemical Structure

Molecular Weight(MW): 641.61

PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with IC50 of 9 nM in cell-free assays, >50-fold selectivity for c-Met than RTKs or STKs.

Size Price Stock Quantity  
USD 70 In stock
USD 120 In stock
USD 470 In stock
USD 997 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 28 Publications

Purity & Quality Control

Choose Selective c-Met Inhibitors

Biological Activity

Description PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with IC50 of 9 nM in cell-free assays, >50-fold selectivity for c-Met than RTKs or STKs.
c-Met [1]
(Cell-free assay)
RON [1]
(Cell-free assay)
Flk1 [1]
(Cell-free assay)
9 nM 68 nM 200 nM
In vitro

PHA-665752 significantly inhibits c-Met kinase activity with Ki of 4 nM, and exhibits >50-fold selectivity for c-Met compared with various tyrosine and serine-threonine kinases. PHA-665752 potently inhibits the HGF-stimulated c-Met autophosphorylation with IC50 of 25-50 nM. PHA-665752 also significantly blocks HGF- and c-Met-dependent functions such as cell motility and cell proliferation with IC50 of 40-50 nM and 18-42 nM, respectively. In addition, PHA-665752 potently inhibits HGF-stimulated or constitutive phosphorylation of mediators of downstream of c-Met such as Gab-1, ERK, Akt, STAT3, PLC-γ, and FAK in multiple tumor cell lines. [1] PHA-665752 inhibits cell growth in TPR-MET-transformed BaF3 cells with IC50 of <60 nM, and inhibits constitutive cell motility and migration by 92.5% at 0.2 μM. Inhibition of c-Met by PHA665752 (0.2 μM) also induces cell apoptosis of 33.1% and G1 cell cycle arrest with cells in G1 phase increasing from 42.4% to 77.0%. PHA665752 can cooperate with rapamycin to inhibit cell growth of TPR-MET-transformed BaF3 cells and non-small cell lung cancer H441 cells. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-SNU-5 MlG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\nbGJQUUN3ME2wMlEzOzd3IN88US=> M1jXPHNCVkeHUh?=
LB2241-RCC MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPnfmVQUUN3ME2wMlE2PzB{IN88US=> NHzlOItUSU6JRWK=
KINGS-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH[2NYxKSzVyPUCuN|U6OTFizszN MXnTRW5ITVJ?
ALL-PO Mmj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwOEGyO|ch|ryP MkDkV2FPT0WU
SK-LMS-1 NF71fmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LtSWlEPTB;MD64PVg1PiEQvF2= MXXTRW5ITVJ?
MV-4-11 MlPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rEXWlEPTB;MT6yPVQ4KM7:TR?= M2TVSHNCVkeHUh?=
MRK-nu-1 NX\KZVlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXK0eY5XUUN3ME2yMlQxODV4IN88US=> Mn7kV2FPT0WU
ES1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTNwM{S4OlYh|ryP NWewUplkW0GQR1XS
NOS-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUixPIg{UUN3ME20MlM6QDZ5IN88US=> MlnLV2FPT0WU
Becker Mn7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLSfpZZUUN3ME21MlI1PjZizszN M1PNPHNCVkeHUh?=
NCI-SNU-1 NVLN[pFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTVwNkO3N|Mh|ryP M2nubnNCVkeHUh?=
EW-22 NIfVdm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7WNHFFUUN3ME23Mlc{PjF2IN88US=> MmfyV2FPT0WU
A498 NGPmcmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnEb5N4UUN3ME24MlI5PDR4IN88US=> MYPTRW5ITVJ?
EW-16 NVf2blN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TpW2lEPTB;OT62OVQ{KM7:TR?= Mmm1V2FPT0WU
ETK-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTFyLkK5N|Eh|ryP MWPTRW5ITVJ?
NCI-H1395 NIfoVIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPmTWM2OD1zMD64NFI1KM7:TR?= MYHTRW5ITVJ?
HT-144 MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTF2LkKxOlMh|ryP MnjYV2FPT0WU
ES5 NWj2U2t2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTF2LkS2O{DPxE1? M{X6SXNCVkeHUh?=
KNS-81-FD M3j4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXMRZI4UUN3ME2xOU42QDR7IN88US=> MnLrV2FPT0WU
TE-15 NX\yb4g2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1uxbGlEPTB;MU[uOVc4OSEQvF2= NUfUXpp3W0GQR1XS
EoL-1-cell NYDFbGs2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vXXWlEPTB;MUiuOFU1PSEQvF2= M2fGR3NCVkeHUh?=
NCI-H720 M1PHeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XsUWlEPTB;MUiuO|cyKM7:TR?= MoL0V2FPT0WU
NB14 MnryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHWyTpFKSzVyPUG5MlU1OjVizszN NEf1TY5USU6JRWK=
KE-37 NH\3fWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjWNFN{UUN3ME2xPU45OjN|IN88US=> NWflOmUyW0GQR1XS
LXF-289 NFHWXGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTF7Lki2Nlkh|ryP M37HWHNCVkeHUh?=
RPMI-8402 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjCO3Q{UUN3ME2yNE4{OjZ7IN88US=> NWHHS2JuW0GQR1XS
SK-N-DZ M{LDdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTJzLkKxN|Eh|ryP M4rWcXNCVkeHUh?=
TE-11 M1zMNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrte2pNUUN3ME2yOk4xPjlizszN MXHTRW5ITVJ?
COLO-800 NHWxWVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Ta[mlEPTB;MkeuNVch|ryP M3\C[XNCVkeHUh?=
MOLT-13 MojDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\QSmlEPTB;MkeuNVg1PyEQvF2= MmXyV2FPT0WU
697 M1SzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHiPVVKSzVyPUK4Mlc3OzNizszN M{fGcXNCVkeHUh?=
VA-ES-BJ NFH2O2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmruTWM2OD1{OT6zO|I6KM7:TR?= NXOzdJV[W0GQR1XS
EW-13 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTJ7LkWwOFUh|ryP NIPpSm1USU6JRWK=
NB7 M1TOTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHtXGhKSzVyPUOyMlI3PjVizszN NFHocFBUSU6JRWK=
MONO-MAC-6 NF3sWYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LnTWlEPTB;M{KuPFc6PSEQvF2= M4TjZnNCVkeHUh?=
SW962 M1jBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnYe3ZnUUN3ME2zN{41PTF|IN88US=> NEj0SnFUSU6JRWK=
KS-1 NXLi[WNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWf4TowyUUN3ME2zN{46PDhzIN88US=> NWDFdIo3W0GQR1XS
KU812 MkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rPOGlEPTB;M{SuOVcxOiEQvF2= M1TYcHNCVkeHUh?=
NCI-H510A MmfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTNUI1KSzVyPUO4MlIxOzJizszN M1vRfHNCVkeHUh?=
EW-18 NUDZW|N6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2i2VGlEPTB;NECuPFMxOyEQvF2= M2[4R3NCVkeHUh?=
CCRF-CEM MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrIN5JKSzVyPUSyMlI4QTdizszN M{DSenNCVkeHUh?=
HH M1n6fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vtbWlEPTB;NEOuOVA3QSEQvF2= NGT5dXVUSU6JRWK=
NCI-H2171 MoT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmD1TWM2OD12Nj6wNlczKM7:TR?= MYDTRW5ITVJ?
LC-2-ad Ml6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jHNWlEPTB;NEmuNVQyOyEQvF2= MVjTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Administration of PHA-665752 induces a dose-dependent tumor growth inhibition of S114 xenografts by 20 %, 39% and 68%, at dose of 7.5, 15, and 30 mg/kg/day, respectively. [1] PHA665752 treatment significantly reduces the tumor growth of NCI-H69, NCI-H441 and A549 in mouse xenografts by 99%, 75%, and 59%, respectively. PHA665752 also significantly inhibits angiogenesis by >85%, due to decreasing the production of vascular endothelial growth factor and increasing the production of the angiogenesis inhibitor thrombospondin-1. [3]


Kinase Assay:[1]
+ Expand

In vitro enzyme assay:

The c-Met kinase domain GST-fusion protein is used for the c-Met assay. The IC50 value of PHA-665752 for the inhibition of c-Met is based on phosphorylation of kinase peptide substrates or poly-glu-tyr in the presence of ATP and divalent cation (MgCl2 or MnCl2 10-20 mM). The linear range (i.e., the time period over which the rate remains equivalent to the initial rate) is determined for c-Met, and the kinetic measurement and IC50 determination are performed within this range.
Cell Research:[1]
+ Expand
  • Cell lines: S114, GTL-16, NCI-H441, and BxPC-3
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 18, or 72 hours
  • Method: For proliferation assays, cells are grown in medium with 0.1% FBS for 48 hours after which they are treated with various concentrations of PHA-665752 in HGF (50 ng/mL) in a medium containing 2% FBS. After 18 hours, cells are incubated with BrdUrd for 1 hour, fixed, and stained with anti-BrdUrd peroxidase-conjugated antibody, and plates are read at 630 nm. For apoptosis assays, cells are grown in medium with 2% FBS in presence and absence of HGF (50 ng/mL) and various concentrations of PHA-665752 for 72 hours. After 72 hours, a mixture containing ethidium bromide and acridine orange is added, and apoptotic cells (bright orange cells or cell fragments) are counted by fluorescence microscopy.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female athymic mice (nu/nu) bearing S114 or GTL-16 tumor xenografts
  • Formulation: Formulated in vehicle (L-lactate (pH 4.8) and 10% polyethylene glycol)
  • Dosages: ~30 mg/kg/day
  • Administration: Injection via bolus i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 128 mg/mL (199.49 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+castor oil
For best results, use promptly after mixing.

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 641.61


CAS No. 477575-56-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I need to use S1070 for intraperitoneal application in mice. Could you tell me the solvent you use, please?

  • Answer:

    The highest concentration of PHA-665752 (S1070) in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O is 5mg/ml. If you want to get higher concentration, the concentration of DMSO and PEG will be higher. For example, it can be dissolved in 8% DMSO+50% PEG 300+5% Tween 80+ddH2O at 10mg/ml clearly.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

Related c-Met Products4

Tags: buy PHA-665752 | PHA-665752 supplier | purchase PHA-665752 | PHA-665752 cost | PHA-665752 manufacturer | order PHA-665752 | PHA-665752 distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID